Last edition
News about "Chugai Pharmaceutical "
Chugai Pharma's Avastin Secures Approval in Japan for Additional Indication
Chugai Pharma’s Avastin has received approval in Japan for an additional indication, becoming the world’s first therapeutic option for neurofibromatosis type 2. The approval is supported by positive phase 2 clinical study results.
Chugai Pharmaceutical | 22/06/2026 | By News Bureau
Chugai Files Regulatory Application in Japan for IgA Nephropathy Drug Sparsentan
Chugai Pharmaceutical has applied for regulatory approval in Japan for sparsentan, a dual-action oral therapy for IgA nephropathy. Clinical studies showed significant reductions in proteinuria and potential benefits in preserving kidney function, offering hope for patients with limited treatment options.
Chugai Pharmaceutical | 20/06/2026 | By News Bureau
Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan
Chugai Pharmaceutical has received regulatory approval in Japan for the expanded use of Alecensa (alectinib) in advanced or recurrent ALK fusion-positive solid tumours, marking the world’s first tumour-agnostic approval for an ALK inhibitor.
Chugai Pharmaceutical | 19/05/2026 | By News Bureau | 118
Chugai Pharmaceutical Files Japan Approval for Gazyva in Idiopathic Nephrotic Syndrome
Chugai Pharmaceutical files a regulatory application in Japan for Gazyva to treat Idiopathic Nephrotic Syndrome (INS), based on phase 3 INShore study results.
Chugai Pharmaceutical | 15/05/2026 | By News Bureau
Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD
Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.
Chugai Pharmaceutical | 25/03/2026 | By News Bureau | 219
Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.
Chugai Pharmaceutical | 24/03/2026 | By News Bureau | 140
Chugai Launches Elevidys Gene Therapy for Duchenne Muscular Dystrophy in Japan
Elevidys receives conditional approval and NHI listing for ambulatory DMD patients aged three to under eight years; launch backed by Phase III EMBARK study and strengthened safety measures.
Chugai Pharmaceutical | 23/02/2026 | By News Bureau | 257
Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia
Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.
Chugai Pharmaceutical | 24/10/2025 | By Dineshwori | 560
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy